ONCY

Business Context and Reporting Period

Company: Oncolytics Biotech Inc.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2002
Business Overview: Oncolytics is a development-stage biopharmaceutical company focused on the discovery and development of REOLYSIN®, a human reovirus-based therapeutic designed to treat cancers with an activated Ras pathway. The company has no commercial products and relies on equity financing and grants to fund research and development (R&D).

Key Financial Metrics (Year Ended Dec 31, 2002)

Note: All figures are in Canadian Dollars unless otherwise specified. The long-term debt is a non-interest-bearing loan from the Alberta Heritage Foundation repayable upon product sales.

Material Changes vs. Prior Period

• Revenue: The company generated no operating revenue in 2002 or 2001. Interest income decreased by approximately 68% to $208,867 due to lower average cash balances and reduced interest rates.
• Expenses: Total expenses decreased slightly to $6.96 million from $7.14 million. Research and development (R&D) expenses dropped to $4.28 million (61.5% of total) from $5.12 million (71.7% of total). The 2001 R&D figure included a one-time $1.0 million milestone payment to vendors, which was not incurred in 2002.
• Liquidity: Cash balances declined by approximately $6.65 million to $8.32 million, driven by operating losses and capital expenditures, partially offset by a private placement in December 2002 raising net proceeds of $1.77 million.
• Investments: The company acquired investments in Transition Therapeutics Inc. and BCY LifeSciences Inc. during 2002, recorded at a total cost of approximately $4.84 million.

Guidance, Outlook, and Risks

Outlook and Guidance: Management anticipates continued significant losses in 2003 and the foreseeable future. The company plans to escalate clinical trial activities, including a systemic delivery trial for REOLYSIN®. Management believes current cash resources are sufficient to fund operations into early 2004. Future capital requirements will likely be met through equity issuances, strategic partnerships, or debt financing.

Key Risks and Contingencies:

• Development Risk: REOLYSIN® is in the clinical trial stage. There is no assurance that the product will prove safe or effective in humans or obtain regulatory approval (FDA/Health Canada).
• Financing Risk: The company has no operating revenue and requires additional financing to continue R&D. There is no assurance that funding will be available on acceptable terms.
• Manufacturing Dependency: The company relies on a single contract manufacturer (BioReliance) for clinical supplies. Disruptions could delay trials.
• Contingent Liabilities: The company has a contingent obligation to pay a $1.0 million milestone payment upon the first regulatory approval for REOLYSIN®. Additionally, royalty payments may be due to vendors upon product sales.
• Product Liability: The company currently has no product liability insurance, which could inhibit commercialization.

Investor Verification Checklist

• Cash Runway: Verify if the $8.3 million cash balance is sufficient to fund the planned escalation of clinical trials through early 2004 without immediate dilution.
• Clinical Trial Progress: Monitor the status of the Phase I/II trials for glioma and prostate cancer, and the initiation of the systemic delivery trial.
• Regulatory Milestones: Track progress toward Investigational New Drug (IND) submissions and potential regulatory approvals, which trigger the $1.0 million contingent milestone payment.
• Financing Needs: Assess the likelihood and terms of future equity offerings or strategic partnerships required to fund operations beyond early 2004.
• Investment Valuation: Review the carrying value of investments in Transition Therapeutics and BCY LifeSciences, noting the unrealized losses recorded under U.S. GAAP ($2.47 million).